Medifast (MED) Cash & Equivalents (2010 - 2026)

Medifast (MED) has 17 years of Cash & Equivalents data on file, last reported at $71.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 22.01% year-over-year to $71.5 million; the trailing twelve-month figure through Mar 2026 stood at $71.5 million (down 22.01% YoY), and the FY2025 full-year result was $89.3 million, down 1.79% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $71.5 million, down from $89.3 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $147.4 million in Q2 2023 and bottomed at $61.1 million in Q2 2022.
• The 5-year median for Cash & Equivalents is $97.5 million (2024), against an average of $98.8 million.
• The widest annual swing landed in 2022, when Cash & Equivalents slumped 68.19%; it then surged 141.37% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $87.7 million in 2022, then advanced by 7.7% to $94.4 million in 2023, then declined by 3.72% to $90.9 million in 2024, then decreased by 1.79% to $89.3 million in 2025, then declined by 19.9% to $71.5 million in 2026.
• The last three Cash & Equivalents figures came in at $71.5 million (Q1 2026), $89.3 million (Q4 2025), and $99.5 million (Q3 2025), per Business Quant data.

Peer Comparison